← Eichor
Study identifier: NCT06541080 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Collection of Liquid Biopsy Samples of Neuroendocrine Neoplasms (NEN) Patients - Collection of NET (CollectNET) 2.0, a Study by the BE-FORCE Consortium

Condition: Neuroendocrine Neoplasms  ·  Sponsor: University Hospital, Antwerp

PhaseN/A
Planned participants550
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The CollectNET 2.0 by BE-FORCE is a prospective, multicentric, interventional study in which liquid biopsies will be collected from neuroendocrine neoplasms (NEN) patients to create an extensive biobank that will be used for current and future circulating cell-free DNA (ccfDNA) analyses. Two sampling groups will be created: the "Regular Sampling Group" and the "Intensive Sampling Group". Upon participation, up to four additional blood tubes (max. total of 32.5mL) will be collected at each timepoint as specified below. These include 3 Streck Cell-Free DNA tubes (10 mL each) which will be used for the extraction of ccfDNA and 1 PreAnalytiX (PAXgene)® Blood RNA tube (2.5 mL). All NEN patients in one of the participating hospitals who have measurable tumor burden on imaging will be asked to participate in our study and will be included in the "Regular Sampling Group". If additionally, the patient is (i) diagnosed with a histologically confirmed NEN of World Health Organisation (WHO) 2019 grade 1-3 neuroendocrine tumor (NET) or neuroendocrine carcinoma (NEC) from pancreatic, colorectal or small intestinal origin and (ii) is starting any kind of 1st line systemic treatment (e.g. somatostatin analogues, targeted therapy, chemotherapy, etc.), they will be followed up more intensively as per the "Intensive Sampling Group". If during follow-up in this "Intensive Sampling Group" patients have disease progression or have completed follow-up for 3 years in this group, their follow-up will…

This description comes directly from the study's public registry record.

Talk to the study team

Siddharth Chhajlani  ·  03436  ·  siddharth.chhajlani@uantwerpen.be

isolde Van der Massen  ·  03821  ·  netwerkstudies@uza.be

Always discuss trial participation with your own doctor first.

Locations (8)

AZ RivierenlandRumst, Antwerp, BelgiumNot Yet Recruiting
VITAZSint-Niklaas, East-Flanders, BelgiumNot Yet Recruiting
University Hospital LeuvenLeuven, Flemish Brabant, BelgiumNot Yet Recruiting
Ziekenhuis Netwerk Antwerpen (ZNA)Antwerp, BelgiumNot Yet Recruiting
Gasthuiszusters Ziekenhuizen (GZA)Antwerp, BelgiumNot Yet Recruiting
AZ MonicaAntwerp, BelgiumNot Yet Recruiting
AZ KlinaBrasschaat, BelgiumNot Yet Recruiting
Antwerp University Hospital (UZA)Edegem, BelgiumRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06541080